Selank vs noopept: how the two peptides actually compare

Last updated 2026-07-26

what are selank and noopept, and are they the same kind of thing?

No, and the confusion is understandable because both got developed in Russia, both get sold as research peptides or nootropics in the West, and both show up on the same gray-market vendor sites. But chemically and pharmacologically they're pretty different animals. Selank is a synthetic heptapeptide, an analog of the endogenous immunomodulator tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It's a short chain of amino acids (Thr-Lys-Pro-Arg-Pro-Gly-Pro) with a few extra residues tacked onto tuftsin to make it more stable in the body ^[1]. It's administered intranasally in the Russian studies and sold that way in the compounded/research market. Noopept (INN name omberacetam, also called GVS-111) is a small molecule, an ethyl ester derivative structurally related to the racetam family, though it isn't itself a racetam and isn't structurally close to piracetam. It was developed by the same Russian research institutions (the Institute of Pharmacology, Russian Academy of Medical Sciences) in the 1990s and is registered in Russia as a prescription nootropic sold under the brand name Noopept ^[2]. It's typically taken orally as a tablet, not injected or sprayed. So one is a peptide hormone analog aimed at the stress and immune axis. The other is a synthetic small molecule aimed at cognition and neuroprotection. Different drug classes, different delivery routes, different regulatory footprint even inside Russia.

what is each one actually approved for in russia?

Selank has Russian Ministry of Health registration as an anxiolytic, sold under the brand name Selank as a 0.15% intranasal solution, indicated for anxiety disorders and neurotic and cyclothymic conditions ^[1]. It doesn't carry the sedation or dependence profile associated with benzodiazepines in the Russian trial literature, and that's the main selling point in the sourcing that markets it. Noopept has Russian registration as a nootropic, marketed for cognitive impairment following traumatic brain injury, and for mild cognitive disorders of vascular and traumatic origin, plus off-label enthusiast use for memory and focus ^[2]. The Russian State Register of Medicines lists Noopept (omberacetam) as an approved prescription drug with these indications. Neither approval is an FDA approval and neither drug has been through the FDA's New Drug Application process. Russian Ministry of Health registration reflects a different regulatory bar (different trial requirements, different post-market surveillance standards) than the process the FDA runs for U.S. drugs ^[3]. That distinction matters a lot if you're trying to decide how much weight to put on the labeled indications.

how strong is the clinical evidence for each one?

Selank's clinical literature is largely Russian and not replicated in Western trials. That's the single most important thing to internalize before you spend money on it. The studies that exist, including trials on generalized anxiety disorder patients and comparisons against benzodiazepines like Phenazepam, come out of Russian institutions, are published mostly in Russian-language journals or Russian-affiliated English abstracts, and use small samples (often under 100 patients) ^[4]. No major Western university or NIH-funded lab has run an independent randomized controlled trial on selank in anxiety patients. Noopept's evidence base has a similar shape but slightly more Western-visible data. A 2008 study published in Human Psychopharmacology, run by Russian researchers, compared noopept against piracetam in patients with mild cognitive impairment of vascular origin and reported that Noopept treatment produced measurable improvement on cognitive and anxiety-related scales over piracetam, though the trial was open-label rather than double-blind for part of it and again came out of a Russian research group ^[5]. There's also a body of Russian animal pharmacology on noopept's neuroprotective and anti-amnesic effects, which is where a lot of the mechanistic claims originate, not from human outcome data. Neither drug has a Cochrane review, a large multi-site RCT, or FDA-reviewed data behind it. If you're used to reading Western psychiatry trial standards (double-blind, placebo-controlled, pre-registered, hundreds of subjects, published in a journal like JAMA Psychiatry or The Lancet Psychiatry), you won't find that here for either compound. What you'll find is a real but thin research tradition, mostly domestic to Russia, with real pharmacology behind it but real gaps in independent replication.

selank vs noopept: mechanism of action compared

Selank's proposed mechanism runs through the brain-derived neurotrophic factor (BDNF) system and enzyme regulation. Russian pharmacology papers describe it as modulating the expression of genes involved in serotonin and GABAergic signaling and affecting peptidase activity that breaks down enkephalins, which is the tuftsin-family angle, since tuftsin itself is an immunomodulatory tetrapeptide ^[1]. The anxiolytic effect in animal models shows up without the same GABA-A receptor binding that benzodiazepines rely on, which is the basis for claims that it doesn't cause the sedation or withdrawal issues seen with drugs like diazepam. Noopept's proposed mechanism is different: animal studies suggest it acts partly through modulating AMPA and NMDA glutamate receptor activity and increasing NGF and BDNF expression in the hippocampus, more in line with a cognitive-enhancement and neuroprotective story than an anxiety story ^[2][5]. Some Russian sources also describe it as having a rapid antioxidant effect in animal models of oxidative stress. | | Selank | Noopept |

selank vs semax: how does that comparison fit in?

People frequently lump selank in with semax because both are Russian-developed peptides from overlapping research institutions and both get marketed together in the same nootropic-peptide category. But semax is a heptapeptide derived from ACTH (adrenocorticotropic hormone), not from tuftsin, and its Russian approval and use case leans toward cognitive and neuroprotective indications (post-stroke recovery, attention deficit) more than pure anxiety treatment ^[6]. Selank is the calmer, anxiety-leaning sibling; semax is the more stimulating, focus-leaning sibling in how the Russian literature and the Western enthusiast community describe them. If your main goal is anxiety without sedation, selank's Russian trial history points there more directly. If your goal is attention and processing speed, semax's literature leans that direction, and it's closer in stated purpose to noopept than selank is. For a longer treatment of that specific pairing, see selank vs semax and semax vs selank.

how do the side effect profiles compare?

Selank's Russian trial data and animal toxicology studies describe a low side effect burden at the doses studied, mostly mild and transient: nasal irritation from the intranasal spray, occasional headache, and rare reports of drowsiness ^[1][4]. It hasn't shown the dependence, tolerance, or withdrawal pattern documented with benzodiazepines in the same Russian anxiety-trial literature, which is the main comparative claim made in its favor. For the fuller rundown, see selank side effects. Noopept's reported side effects in the Russian literature include occasional irritability, headache, and sleep disturbance at higher doses, along with rare reports of gastrointestinal discomfort ^[2][5]. Because it's an oral small molecule with actual first-pass liver metabolism, the guidance around interactions (other CNS-active drugs, stimulants) is a bit more explicit in the Russian prescribing information than what exists for selank. Neither compound has a solid, independent, Western pharmacovigilance record. No FDA MedWatch adverse event database entry exists for either because neither is an FDA-approved drug, so what you're relying on for safety data is the Russian clinical literature plus scattered self-report from the research-chemical community, not a regulator-monitored safety surveillance system ^[3].

which one is better for anxiety?

Based on stated indication and the trial history, selank is the one aimed specifically at anxiety. The Russian GAD trials and the benzodiazepine-comparison studies were designed around anxiety and neurotic disorder endpoints, using instruments like the Hamilton Anxiety Rating Scale ^[4]. Noopept's studies target cognitive impairment scales, not anxiety scales, even though some of that data reportedly showed secondary anxiolytic-like effects in vascular cognitive impairment patients ^[5]. If your actual complaint is anxiety, generalized worry, or the kind of low-grade nervous-system tension that makes you want something 'like a benzo but not a benzo,' selank's literature at least points in the right direction even if it's thin by Western standards. Noopept's anxiety angle is a side effect of a cognition-focused drug, not its design target.

which one is better for focus or cognition?

Noopept is the one built around cognition. The 2008 Human Psychopharmacology trial and the Russian post-TBI cognitive rehab literature both use memory, attention, and processing-speed endpoints, and the vascular cognitive impairment comparison against piracetam is noopept's flagship data point ^[5]. Enthusiast reports (not clinical data, just forum and market reporting) describe a faster subjective onset than piracetam-family racetams, sometimes within 15 to 20 minutes, though there's no controlled pharmacokinetic study confirming that timeline in humans. Selank isn't positioned as a cognitive enhancer in the Russian regulatory documents, though some of the BDNF-related animal data has been used to argue for secondary cognitive benefits, mostly by extension of BDNF's known role in neuroplasticity, not from direct human cognition trials on selank itself. If focus and memory are the actual goal, noopept's literature is the more directly relevant one, thin as it is.

can you take selank and noopept together?

There's no published human trial on combining the two, so any stacking protocol you see online is anecdotal, not evidence-based. The theoretical case people make is that they hit different systems (peptide/BDNF/anxiety axis versus small-molecule/glutamate/cognition axis) and so might complement each other, but that's an inference from separate mechanism studies, not a tested combination. If you're going to experiment anyway, the standard harm-reduction logic applies: start with one compound at a time, at the low end of what's described in the Russian dosing literature, track how you respond, and only add the second agent after you understand the first one's effect on you. Check selank dosage for the dose ranges used in the Russian intranasal trials, and look at selank semax injection if you're comparing intranasal against injectable routes, since route of administration changes the practical logistics a lot more than most stacking guides admit.

is either one legal or fda-approved in the united states?

Neither selank nor noopept is FDA-approved as a drug in the United States. Neither shows up in the FDA's Orange Book of approved drug products, and neither has an NDA on file ^[3]. In practice they get sold in the U.S. through the research-chemical and compounding-pharmacy markets, sometimes marketed as 'not for human consumption' research compounds, sometimes available through compounding pharmacies that work under a prescriber's order. That's a meaningfully different legal posture than an FDA-approved drug, and it means the manufacturing, purity testing, and labeling accuracy you'd take for granted with an approved pharmaceutical aren't guaranteed here. If you go this route, the safer path is a provider-reviewed source rather than an anonymous research-chemical vendor. Selank covers the regulatory landscape in more depth, and Selank Co's provider-reviewed listings point to fulfillment through a licensed compounding pharmacy partner rather than unregulated gray-market suppliers, which at least gets you closer to pharmaceutical-grade sourcing even though it doesn't change the underlying FDA-approval status.

what does a typical dose look like for each?

In the Russian clinical literature, selank is dosed intranasally, commonly cited around 250 to 3000 micrograms per day split across two or three administrations in trial protocols, using the 0.15% solution ^[1][4]. Exact protocols vary by study and indication, and there's no FDA-reviewed dosing label to defer to, so anything you see quoted as a 'standard dose' is really a summary of what various small Russian trials used, not a regulatory-grade dosing guideline. Noopept in the Russian prescribing literature is typically dosed orally at 10 to 20 mg, two to three times daily, with total daily doses in trials often landing around 20 to 40 mg ^[2][5]. That's a much smaller absolute dose than most racetam-family compounds (piracetam trials use gram-level dosing), which is part of why it gets described as more potent per milligram, though 'potent' here is a pharmacological description, not a claim about better outcomes. For exact dosing breakdowns, timing, and titration approaches used in the Russian trials, selank dosage has the fuller numbers for selank specifically.

how should you decide which one to try, if either?

Start with what problem you're actually trying to solve. If it's anxiety, worry, or stress reactivity, selank's Russian trial history is aimed at that target directly, and the non-benzodiazepine mechanism is the actual argument in its favor, thin as the trial base is. If it's memory, attention, or general cognitive sharpness, noopept's literature is built around those endpoints, even though it's also mostly Russian and mostly small-sample. What neither one gives you is Western-grade certainty. No FDA approval, no large independent RCT, no Cochrane review, on either compound. That's not a reason to write them off entirely, since Russian pharmacology has produced real drugs with real registered indications and decades of clinical use inside that system. But it is a reason to keep your expectations calibrated to 'promising but under-replicated' rather than 'proven.' If you want the deepest read on selank's specific evidence quality before deciding anything, that's the right next stop.

Frequently asked questions

is noopept stronger than selank?

They're not directly comparable because they target different systems: noopept for cognition, selank for anxiety. Per-milligram, noopept is more potent than older racetams like piracetam, but 'stronger' doesn't mean much across two drugs with different intended effects and no head-to-head human trial comparing them directly.

can selank and noopept be taken together safely?

No published human trial has tested the combination, so safety data doesn't exist beyond each compound's individual Russian trial record. Anecdotal stacking reports exist online but aren't clinical evidence. If you experiment, introduce one at a time at low doses and track your response before adding the second.

which is better for social anxiety, selank or noopept?

Selank's Russian trial literature targets generalized anxiety and neurotic disorders directly, using anxiety rating scales, while noopept's trials are built around cognitive impairment endpoints with anxiety as a secondary finding at best. For anxiety specifically, selank's evidence base is the more directly relevant one, though still Russian-only and unreplicated in the West.

does noopept help with adhd-like focus issues?

There's no Russian or Western RCT testing noopept specifically for ADHD. Its trial history covers vascular and post-TBI cognitive impairment, not attention-deficit disorders. Any ADHD-focus claims for noopept come from enthusiast reports and extrapolation from cognition trials, not from studies on ADHD populations.

is selank fda approved in the us?

No. Selank is registered with the Russian Ministry of Health as an anxiolytic, which is a different regulatory process than FDA approval. It has never gone through an FDA New Drug Application, and it doesn't appear in the FDA's Orange Book of approved drugs.

is noopept the same as piracetam?

No. Noopept is structurally distinct from piracetam even though it's often grouped with the racetam family in casual conversation. Russian trials found noopept produced measurable cognitive improvement over piracetam in vascular cognitive impairment patients at much lower doses, but it's a different molecule with its own registration.

how long does it take noopept or selank to work?

Neither has a controlled human pharmacokinetic study establishing a precise onset window. Enthusiast reports describe noopept's subjective effects appearing within 15 to 30 minutes orally, and selank's intranasal effects appearing within a similar window, but these are self-reports, not measured trial data.

what's the difference between selank and semax?

Selank is a tuftsin-derived peptide aimed at anxiety; semax is an ACTH-derived peptide aimed more at cognition, attention, and neuroprotection after stroke. Both are Russian-developed and share overlapping research history, but they target different indications. See selank vs semax for the full comparison.

are selank and noopept legal to buy in the united states?

They're not FDA-approved drugs, but they're commonly sold through research-chemical vendors and some compounding pharmacies. Buying through an unregulated research-chemical vendor carries real purity and labeling risk. A provider-reviewed source fulfilled by a licensed compounding pharmacy is a safer path than an anonymous online vendor.

do selank and noopept show up on any doping or banned substance list?

Neither selank nor noopept currently appears by name as a specifically named prohibited substance on major anti-doping lists in the way anabolic steroids or stimulants do, but competitive athletes should check the current World Anti-Doping Agency prohibited list directly before use, since peptide categories get revised.

why are most selank and noopept studies only in russian?

Both compounds were developed at Russian research institutions (the Institute of Molecular Genetics and the Institute of Pharmacology under the Russian Academy of Sciences) and were registered and studied primarily within the Russian domestic pharmaceutical system, which is why the bulk of trial publications appeared in Russian-language journals rather than international ones.

which has better safety data, selank or noopept?

Both have similarly thin, Russia-only safety literature with no FDA pharmacovigilance record. Selank's trials report a low rate of mild effects like nasal irritation and headache; noopept's report occasional irritability and sleep disturbance at higher doses. Neither has independent Western safety monitoring, so real-world data outside Russia is limited.

Sources

1. PubMed - Molecular Mechanisms of Selank: Selank is a synthetic heptapeptide analog of tuftsin studied for anxiolytic effects via BDNF and enzyme modulation
2. PubMed - Noopept pharmacology overview: Noopept is a synthetic nootropic developed in Russia with proposed glutamate receptor and NGF/BDNF-related mechanisms
3. FDA - Development & Approval Process (Drugs): Neither selank nor noopept has completed the FDA drug approval process required for U.S. marketing
4. PubMed - Selank anxiolytic clinical trial data: Russian trials of selank in anxiety patients used small samples and Hamilton Anxiety Rating Scale-type endpoints
5. Human Psychopharmacology - Noopept vs piracetam in vascular cognitive impairment: A Russian-run trial found Noopept produced greater improvement than piracetam in patients with mild cognitive impairment of vascular origin
6. PubMed - Semax pharmacology and clinical use: Semax is an ACTH-derived peptide studied in Russia mainly for cognitive and neuroprotective indications including post-stroke recovery